Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05973331 · ClinicalTrials.gov registry record
Prospective Validation of an EHR-based Pancreatic Cancer Risk Model
A clinical trial of Pancreatic Adenocarcinoma and Predictive Cancer Model, sponsored by Beth Israel Deaconess Medical Center.
- Active
- Registry status
- 6,134,060
- Enrollment target
- 1
- Study location
NCT05973331: Active study of Pancreatic Adenocarcinoma and Predictive Cancer Model, sponsored by Beth Israel Deaconess Medical Center.
NCT05973331 is a study of Pancreatic Adenocarcinoma and Predictive Cancer Model that is active but no longer recruiting, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 6,134,060 participants, above the 529-participant average among 62 other Pancreatic Adenocarcinoma trials with a reported enrollment target (1159458% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05973331, a study of Pancreatic Adenocarcinoma and Predictive Cancer Model, is active but no longer recruiting, sponsored by Beth Israel Deaconess Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- 6,134,060 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this prospective observational cohort study is to validate a previously developed pancreatic cancer risk prediction algorith (the PRISM model) using electronic health records from the general population. The main questions it aims to answer are: * Will a pancreatic cancer risk model, developed on routine EHR data, reliably and accurately predict pancreatic cancer in real-time? * What is the average time from model deployment and risk prediction, to the date of pancreatic cancer development and what is the stage of pancreatic cancer at diagnosis? The risk model will be deployed on data from individuals eligible for the study. Each individual will be assigned a risk score and tracked over time to assess the model's discriminatory performance and calibration.
Primary Outcome
To assess the discriminatory performance of PRISM for prospective identification of high-risk individuals for PDAC development. ROCs and AUROC numbers will be calculated for the whole population and groups stratified by age, sex, race, and geographical location.
Conditions Studied
Interventions
- OTHER Pancreatic Cancer Risk Model (PRISM)
Study Locations (1)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,134,060 participants |
| Start Date | 2023-04-21 |
| Est. Completion | 2026-09 |
What the registry record for NCT05973331 still lists
NCT05973331 is an observational study that tracks outcomes without assigning an intervention. Its 6,134,060 participants enrollment target places it among the larger protocols in the corpus, above the 529-participant average among 62 other Pancreatic Adenocarcinoma trials with a reported enrollment target (1159458% higher).
The record links to 2 conditions, with Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Pancreatic Cancer Risk Model (PRISM) is the first listed.
NCT05973331 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05973331 about?
NCT05973331 is a clinical study titled "Prospective Validation of an EHR-based Pancreatic Cancer Risk Model". The goal of this prospective observational cohort study is to validate a previously developed pancreatic cancer risk prediction algorith (the PRISM model) using electronic health records from the general population. The main questions it aims to answer are: * Will a pancreatic cancer risk model, de...
What is the current status of trial NCT05973331?
This trial is currently active not recruiting. The enrollment target is 6,134,060 participants. The study started on 2023-04-21. Estimated completion is 2026-09.
What conditions does trial NCT05973331 study?
This clinical trial studies the following conditions: Pancreatic Adenocarcinoma, Predictive Cancer Model.
What interventions are being tested in trial NCT05973331?
The interventions under investigation include: Pancreatic Cancer Risk Model (PRISM) (OTHER).
Who is sponsoring clinical trial NCT05973331?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05973331 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05973331's enrollment target sits among peer trials
6,134,060 1st of 62 higher than 62 of 62 other Pancreatic Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
RECRUITING · NA
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
RECRUITING · Phase 1
-
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
RECRUITING · Phase 1
-
Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02693223 · 3,892,063 participants
Get With the Guidelines-Stroke Registry
- NCT06803498 · 3,000,000 participants
Delivery Room Intervention and Evaluation Network
- NCT05678699 · 10,000,000 participants · NA
The Effects of Medicaid Policy Interventions on Racial Equity in Severe Maternal Morbidity
- NCT03813862 · 2,000,000 participants
Observational Pharmaco-Epidemiology Research & Analysis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI